Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ekaterina Pak

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Developmental Cell|August 25, 2016
Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer TherapyEkaterina Pak, Rosalind A Segal
Cancer Discovery|September 20, 2017
A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO InhibitorsXuesong Zhao, Ekaterina Pak, Kimberly J Ornell, et al.
Cancer Research|July 2, 2015
RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent TumorsXuesong Zhao, Tatyana Ponomaryov, Kimberly J Ornell, et al.
Neuro-Oncology|May 22, 2019
A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastomaEkaterina Pak, Ethan L MacKenzie, Xuesong Zhao, et al.
Nature Medicine|October 1, 2013
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunitiesMariella Gruber Filbin, Sukriti K Dabral, Maria F Pazyra-Murphy, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Developmental Cell|August 25, 2016
Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer TherapyEkaterina Pak, Rosalind A Segal
Cancer Discovery|September 20, 2017
A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO InhibitorsXuesong Zhao, Ekaterina Pak, Kimberly J Ornell, et al.
Cancer Research|July 2, 2015
RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent TumorsXuesong Zhao, Tatyana Ponomaryov, Kimberly J Ornell, et al.
Neuro-Oncology|May 22, 2019
A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastomaEkaterina Pak, Ethan L MacKenzie, Xuesong Zhao, et al.
Nature Medicine|October 1, 2013
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunitiesMariella Gruber Filbin, Sukriti K Dabral, Maria F Pazyra-Murphy, et al.
Pageof 1